|
US4971791A
(en)
*
|
1985-08-26 |
1990-11-20 |
The Procter & Gamble Company |
Taste masking compositions
|
|
US5843445A
(en)
*
|
1987-06-24 |
1998-12-01 |
Autoimmune, Inc. |
Method of treating rheumatoid arthritis with type II collagen
|
|
US4857337A
(en)
*
|
1988-05-24 |
1989-08-15 |
American Home Products Corp. (Del) |
Enteric coated aspirin tablets
|
|
BR9106114A
(pt)
|
1990-03-02 |
1993-03-09 |
Autoimmune Inc |
Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
|
|
FR2660317B1
(fr)
*
|
1990-03-27 |
1994-01-14 |
Seppic |
Produit filmogene destine a l'enrobage des formes solides; son procede de fabrication et produits revetus de ce produit.
|
|
IL99699A
(en)
|
1990-10-10 |
2002-04-21 |
Autoimmune Inc |
Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
|
|
US5427614A
(en)
*
|
1992-02-14 |
1995-06-27 |
Warner-Lambert Company |
Starch based formulations
|
|
US6224911B1
(en)
*
|
1993-03-16 |
2001-05-01 |
Syntex (U.S.A.) Llc |
Process for the preparation of enteric coated pharmaceutical dosage forms
|
|
US5436011A
(en)
*
|
1993-04-16 |
1995-07-25 |
Bristol-Myers Squibb Company |
Solid pharmaceutical dosage form and a method for reducing abrasion
|
|
US5800831A
(en)
*
|
1993-07-28 |
1998-09-01 |
Pfizer Inc. |
Psoriasis treatment with polymer film
|
|
US6113893A
(en)
*
|
1993-07-28 |
2000-09-05 |
Pfizer Inc. |
Psoriasis treatment
|
|
WO1995006462A1
(en)
*
|
1993-08-30 |
1995-03-09 |
Warner-Lambert Company |
Tablet coating based on a melt-spun mixture of a saccharide and apolymer
|
|
BR9506018A
(pt)
*
|
1994-07-08 |
1997-09-02 |
Astra Ab |
Forma farmacêutica oral de múltipla dosagem unitária em tablete processos para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem e para o tratamento das doenças inflamatórias gastrointestinais em mamiferos e no homem e embalagem de ampola de pressão transversal
|
|
US5733575A
(en)
*
|
1994-10-07 |
1998-03-31 |
Bpsi Holdings, Inc. |
Enteric film coating compositions, method of coating therewith, and coated forms
|
|
US6608035B1
(en)
|
1994-10-25 |
2003-08-19 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US6645943B1
(en)
|
1994-10-25 |
2003-11-11 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5591721A
(en)
*
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
SE9500422D0
(sv)
*
|
1995-02-06 |
1995-02-06 |
Astra Ab |
New oral pharmaceutical dosage forms
|
|
US5683718A
(en)
*
|
1995-04-04 |
1997-11-04 |
Time-Cap Labs, Inc. |
Enteric coated tablet with raised identification character and method of manufacture
|
|
US5856446A
(en)
*
|
1995-07-07 |
1999-01-05 |
Autoimmune Inc. |
Method of treating rheumatoid arthritis with low dose type II collagen
|
|
US7074768B2
(en)
|
1995-08-17 |
2006-07-11 |
Idera Pharmaceuticals, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
|
US6624293B1
(en)
|
1995-08-17 |
2003-09-23 |
Hybridon, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
|
SE9600072D0
(sv)
*
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral formulation of two active ingredients II
|
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
|
SE512835C2
(sv)
*
|
1996-01-08 |
2000-05-22 |
Astrazeneca Ab |
Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
|
|
SE9600071D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral formulation of two active ingredients I
|
|
US5807580A
(en)
*
|
1996-10-30 |
1998-09-15 |
Mcneil-Ppc, Inc. |
Film coated tablet compositions having enhanced disintegration characteristics
|
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
|
US5877309A
(en)
*
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
|
US6809193B2
(en)
|
1997-08-13 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
|
US20070149472A1
(en)
*
|
1997-08-13 |
2007-06-28 |
Mckay Robert |
Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
|
|
AU8771398A
(en)
|
1997-08-19 |
1999-03-08 |
Hybridon, Inc. |
Novel hiv-specific synthetic oligonucleotides and methods of their use
|
|
ATE241341T1
(de)
|
1997-09-10 |
2003-06-15 |
Takeda Chemical Industries Ltd |
Stabilisierte pharmazeutische zusammensetzung
|
|
US6274591B1
(en)
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
|
US6559158B1
(en)
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
|
US7122207B2
(en)
*
|
1998-05-22 |
2006-10-17 |
Bristol-Myers Squibb Company |
High drug load acid labile pharmaceutical composition
|
|
UA69413C2
(uk)
|
1998-05-22 |
2004-09-15 |
Брістол-Майерс Сквібб Компані |
Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
|
|
UA73092C2
(uk)
|
1998-07-17 |
2005-06-15 |
Брістол-Майерс Сквібб Компані |
Таблетка з ентеросолюбільним покриттям і спосіб її приготування
|
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
|
US6878749B2
(en)
*
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
|
AU2001249214A1
(en)
|
2000-03-15 |
2001-09-24 |
The Brigham And Women's Hospital, Inc. |
Suppression of vascular disorders by mucosal administration of heat shock protein peptides
|
|
ES2292594T3
(es)
|
2000-05-24 |
2008-03-16 |
The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services |
E-selectina para tratar o prevenir accidentes cerebrovasculares.
|
|
DE60132256T2
(de)
|
2000-11-20 |
2008-12-24 |
Sorbent Therapeutics, Inc., Vernon Hills |
Wasserabsorbierende polymere und deren verwendung
|
|
US6932861B2
(en)
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
|
AU2002225763A1
(en)
|
2000-11-28 |
2002-06-11 |
Fmc Corporation |
Edible pga(propylene glycol alginate) coating composition
|
|
AU2002314967B2
(en)
*
|
2001-06-05 |
2007-09-20 |
University Of Chicago |
Use of methylnaltrexone to treat immune suppression
|
|
GB0203296D0
(en)
*
|
2002-02-12 |
2002-03-27 |
Glaxo Group Ltd |
Novel composition
|
|
ATE425744T1
(de)
*
|
2002-04-29 |
2009-04-15 |
Supernus Pharmaceuticals Inc |
Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
|
|
US8637512B2
(en)
*
|
2002-07-29 |
2014-01-28 |
Glaxo Group Limited |
Formulations and method of treatment
|
|
CA2493301A1
(en)
*
|
2002-07-29 |
2004-02-12 |
Glaxo Group Limited |
Sustained release formulations comprising lamotrigine
|
|
US20040202755A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Myers Gale D. |
Speckled confection pieces
|
|
PT1615646E
(pt)
|
2003-04-08 |
2015-02-12 |
Progenics Pharm Inc |
Formulações farmacêuticas com metilnaltrexona
|
|
WO2004091622A1
(en)
*
|
2003-04-08 |
2004-10-28 |
Progenics Pharmaceuticals, Inc. |
The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
|
|
MXPA05010821A
(es)
*
|
2003-04-08 |
2006-03-30 |
Progenics Pharm Inc |
Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
|
|
CN1984921B
(zh)
|
2003-06-03 |
2010-06-16 |
Isis药物公司 |
存活蛋白表达的调节
|
|
CA2537103C
(en)
*
|
2003-11-04 |
2010-01-19 |
Shire Laboratories, Inc. |
Once daily dosage forms of trospium
|
|
AU2004289222B2
(en)
|
2003-11-04 |
2010-01-21 |
Supernus Pharmaceuticals Inc. |
Compositions of quaternary ammonium containing bioavailability enhancers
|
|
WO2005074908A1
(en)
|
2004-02-06 |
2005-08-18 |
Borody, Thomas, Julius |
Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
|
|
DK1809302T3
(da)
|
2004-10-20 |
2012-11-26 |
Antisense Therapeutics Ltd |
Antisense-modulation af integrin-alfa-4-ekspression
|
|
WO2006072946A2
(en)
|
2005-01-04 |
2006-07-13 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
|
|
JP2008528497A
(ja)
*
|
2005-01-20 |
2008-07-31 |
プロジェニックス ファーマシューティカルズ，インコーポレーテッド |
メチルナルトレキソンおよび関連化合物の術後性胃腸障害のための使用
|
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
|
ES2714198T3
(es)
|
2005-03-07 |
2019-05-27 |
Univ Chicago |
Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
|
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
WO2006109312A2
(en)
*
|
2005-04-15 |
2006-10-19 |
Vascular Biogenics Ltd. |
Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
|
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
|
US20070098790A1
(en)
*
|
2005-10-31 |
2007-05-03 |
David Jiang |
Nutritional supplement for the enhancement of the health of the liver
|
|
US7731604B2
(en)
*
|
2006-10-31 |
2010-06-08 |
Taylor Made Golf Company, Inc. |
Golf club iron head
|
|
EP2097487B1
(en)
*
|
2007-01-05 |
2013-02-20 |
Basf Se |
Co-milling organic pigments with fumed silica
|
|
ES2570374T3
(es)
|
2007-03-29 |
2016-05-18 |
Progenics Pharm Inc |
Antagonistas del receptor opioide periférico y usos de los mismos
|
|
MX351611B
(es)
|
2007-03-29 |
2017-10-20 |
Wyeth Llc |
Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
|
|
PT2139890E
(pt)
|
2007-03-29 |
2014-09-03 |
Wyeth Llc |
Antagonistas do receptor opióide periférico e respectivas utilizações
|
|
AU2008251467B2
(en)
*
|
2007-05-11 |
2014-07-31 |
The Trustees Of The University Of Pennsylvania |
Methods of treatment of skin ulcers
|
|
BRPI0721697A2
(pt)
|
2007-05-11 |
2014-08-05 |
Univ Jefferson |
" métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
|
|
BRPI0820528A2
(pt)
*
|
2007-11-13 |
2016-11-08 |
Hercules Inc |
formulação de revestimento entérica dispersável em água para formas de dosagem nutracêuticas e farmacêuticas
|
|
HUE041715T2
(hu)
*
|
2007-12-21 |
2019-05-28 |
Dr Willmar Schwabe Gmbh & Co Kg |
Ginkgo biloba levél-kivonat alkalmazása
|
|
WO2009099411A1
(en)
|
2008-02-06 |
2009-08-13 |
Progenics Pharmaceuticals, Inc. |
Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
|
|
WO2009117669A2
(en)
|
2008-03-21 |
2009-09-24 |
The University Of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
|
EP2306829B1
(en)
|
2008-07-01 |
2017-01-04 |
University of Chicago |
Particles containing a peripheral opioid receptor antagonist
|
|
US20100034959A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Vector Corporation |
High solids, high molecular weight polymer coating
|
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
|
WO2012080497A2
(en)
|
2010-12-17 |
2012-06-21 |
Glaxo Group Limited |
Methods of treatment and prevention of eye diseases
|
|
WO2013045352A1
(de)
|
2011-09-30 |
2013-04-04 |
Basf Se |
Verfahren zur herstellung von festen pigmenthaltigen filmüberzugsmitteln in form von granulaten auf basis von magensaftresistenten filmbildnern für pharmazeutische dosierungsformen
|
|
WO2013082275A1
(en)
|
2011-11-30 |
2013-06-06 |
Trustees Of Boston College |
Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
|
|
JP2015500221A
(ja)
|
2011-12-01 |
2015-01-05 |
グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ |
眼疾患の治療および予防方法
|
|
US8277842B1
(en)
*
|
2012-01-20 |
2012-10-02 |
Dart Neuroscience (Cayman) Ltd. |
Enteric-coated HT-2157 compositions and methods of their use
|
|
ES2808862T3
(es)
|
2013-03-27 |
2021-03-02 |
Isarna Therapeutics Gmbh |
Oligonucleótidos TGF-beta modificados
|
|
WO2016061531A1
(en)
|
2014-10-17 |
2016-04-21 |
Salix Pharmaceuticals, Inc. |
Use of methylnaltrexone to attenuate tumor progression
|
|
EP3420084B1
(en)
|
2016-02-26 |
2021-08-04 |
Secarna Pharmaceuticals GmbH & Co. KG |
Novel approach for treating inflammatory disorders
|
|
EP3211081A1
(en)
|
2016-02-26 |
2017-08-30 |
Secarna Pharmaceuticals GmbH & Co. KG |
Novel approach for treating inflammatory disorders
|
|
US10883108B2
(en)
|
2016-03-31 |
2021-01-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
|
AU2017339561B2
(en)
|
2016-10-07 |
2024-02-01 |
Secarna Pharmaceuticals Gmbh & Co. Kg |
Novel approach for treating cancer
|
|
EP3541408A4
(en)
|
2016-11-15 |
2020-06-24 |
The Schepens Eye Research Institute, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS
|
|
US11260048B2
(en)
|
2017-10-03 |
2022-03-01 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
|
JP7416700B2
(ja)
|
2017-11-14 |
2024-01-17 |
ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド |
増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法
|
|
WO2020225186A1
(en)
|
2019-05-03 |
2020-11-12 |
Secarna Pharmaceuticals Gmbh & Co. Kg |
Pd-l1 antisense oligonucleotides for use in tumor treatment
|